Grigoryev E G, Kogan A S, Kolmakov S A, Nechaev E V, Usov S A, Fadeeva T V
Department of Purulent Surgery, Irkutsk Institute of Surgery, Siberia, Russia.
Int Surg. 1998 Jul-Sep;83(3):245-9.
In vitro experiments on fibrin films using purulent exudate from the abdominal cavity of rats with experimental peritonitis demonstrate the fibrinolytic effect of bacterial proteinases immobilized on a polymeric matrix. The application of Imozimaza in the complex treatment of experimental peritonitis by the way of intraperitoneal lavage resulted in reliable lowering of mortality, due to the lysis of fibrinopurulent abdominal contents and better contact between antibacterial agents and peritonitis pathogens. In the clinic, prolonged abdominal proteolysis was applied to 44 patients with postoperative diffuse purulent peritonitis of >24 h duration. Under the conditions of programmable relaparotomy, intraperitoneal Imozimaza infusion led (as in in vitro tests) to the lysis of fibrinopurulent masses, which contained micro-organisms of an order higher than exudate. It was accompanied by increase in the drainage efficacy, absence of fragmentation of abdominal contents and absence of secondary abscesses. The use of Imozimaza on the background of complex antibacterial treatment and combined homeostatic therapy resulted in lowering of mortality from 65.8% to 27.3%. Complications and contra-indications for Imozimaza use in diffuse purulent peritonitis were not registered.
使用实验性腹膜炎大鼠腹腔脓性渗出液对纤维蛋白膜进行的体外实验表明,固定在聚合物基质上的细菌蛋白酶具有纤溶作用。通过腹腔灌洗的方式将伊莫齐马扎应用于实验性腹膜炎的综合治疗中,由于纤维蛋白脓性腹腔内容物的溶解以及抗菌剂与腹膜炎病原体之间更好的接触,使得死亡率可靠降低。在临床上,对44例术后弥漫性脓性腹膜炎持续时间超过24小时的患者应用了延长的腹腔蛋白水解疗法。在可程控再次剖腹手术的情况下,腹腔内注入伊莫齐马扎(如同体外试验)导致纤维蛋白脓性团块溶解,这些团块中所含微生物数量比渗出液中的更高。这伴随着引流效果的提高、腹腔内容物无破碎以及无继发性脓肿。在联合抗菌治疗和联合稳态疗法的背景下使用伊莫齐马扎,使死亡率从65.8%降至27.3%。未记录到伊莫齐马扎用于弥漫性脓性腹膜炎的并发症和禁忌证。